Artificial placenta clarifies risks of medication for pregnant women
Keystone-SDA
Researchers at the University of Bern have developed an artificial placenta. The aim is to use the laboratory model to find out how medication taken by a pregnant woman reaches the unborn child.
+ Get the most important news from Switzerland in your inbox
It is unclear for most drugs whether and to what extent they are passed on to an unborn child, the Swiss National Science Foundation (SNSF) announced on Thursday. Many drugs are therefore not authorised for pregnant women as a precautionary measure, even though they may not pose a risk.
Animal studies are also not always meaningful for these questions, as the placenta – the barrier that protects the foetus from toxins – functions very differently depending on the animal.
To remedy this, a team at the University of Bern led by biomedical scientist Christiane Albrecht has now developed a model in an SNSF-funded project that is intended to better represent the transport of substances in the human placenta than previous methods.
More
More
Science podcast: Can gender diversity create better medicine?
Cells obtained directly after delivery
The model replicates the placental barrier in a plastic vessel. It consists of two different cell layers. A permeable membrane separates the two layers.
The special feature of the laboratory placenta is the use of cells from recent deliveries. These fresh cells from the placenta and umbilical cord have abilities that are lost in cell cultures that have been grown in the laboratory for a long time.
In future, the researchers want to use the model to investigate not only the path of drugs, but also the transport of substances such as iron and cholesterol. Such models could also help to reduce the number of animal experiments.
However, the method is currently still too labour-intensive to be used on a large scale. The next step would be to examine how the system could be simplified for routine use, for example for toxicological tests.
Translated from German by AI/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
